Physician profile
Ezra Hunter
NPI 1265061543
$2,036.71
in general payments reported to CMS, 2019-2025
15 companies · $1,565 in 2025
The $1,565 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.29 · 2022: $266 · 2023: $39.49 · 2024: $127 · 2025: $1,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,732.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $886.71 | 2022-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $428.91 | 2024-2025 | Yeztugo, Descovy, Biktarvy |
| Merck Sharp & Dohme LLC | $130.02 | 2025 | Pifeltro, Delstrigo, Capvaxive |
| Theratechnologies INC. | $103.90 | 2025 | Egrifta, Trogarzo |
| Takeda Pharmaceuticals U.S.A., INC. | $102.68 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $74.96 | 2025 | Rexulti |
| Alkermes, INC. | $54.40 | 2024-2025 | Aristada, Lybalvi |
| Dynavax Technologies Corporation | $43.27 | 2025 | Heplisav-B |
| Novo Nordisk INC | $38.29 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $37.29 | 2024 | Ingrezza |
| Rgh Enterprises LLC | $34.40 | 2025 | |
| Emd Serono, INC. | $31.78 | 2025 | |
| Axsome Therapeutics, INC. | $25.72 | 2025 | Auvelity |
| Exact Sciences Corporation | $23.55 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $20.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ezra Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.